期刊文献+

NADPH氧化酶p22phox与非瓣膜性心衰左室重量指数的相关性分析 被引量:3

Correlation between left ventricular mass index and NADPH oxidase p22phox in patients with non-valvular chronic heart failure
暂未订购
导出
摘要 目的研究非瓣膜性慢性心衰患者吞噬细胞NADPH氧化酶p22phox表达与左室重量指数的相关性,初步探讨该途径导致的氧化应激在非瓣膜性慢性心衰左室重构中的作用。方法收集59例非瓣膜性慢性心衰患者作为心衰组,20例健康体检者为健康对照组。心衰组(HF)患者根据有无左室肥厚(LVM),分为单纯心衰组和心衰合并左室肥厚组。计算其体表面积(BSA)及体质指数(BMI),抽取其空腹外周静脉血,收集吞噬细胞,提取总RNA,进行RT-PCR反应,得到p22phox的最终表达量。同时进行血清高敏C反应蛋白(hs-CRP)、甘油三酯(TG)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、尿素氮(BUN)、肌酐(CR)、尿酸(UA)测定。测量并记录左室舒张末期内径(LVEDd)、左室收缩末期内径(LVEDs)、室间隔厚度(IVST)、左室后壁厚度(LVPWT)、EF值等参数,计算左室质量指数(LVMI)。结果心衰组p22phox表达水平(0.91±0.37)较对照组(0.68±0.33)表达增高,差别有统计学意义(P=0.039,P<0.05);心衰合并左室肥厚组(1.58±0.20)较单纯心衰组p22phox水平(0.71±0.24)增高,差别有统计学意义(P=0.026,P<0.05);p22phox与LVMI呈正相关关系(r=0.508,P<0.05)。结论NADPH氧化酶p22phox与非瓣膜性心衰左室质量指数呈正相关性,在一定程度上可提示左室重构的水平。 Objective To study the correlation between the expression levels of phagocytic NADPH oxidase p22phox subunit and left ventricular mass index (LVMI) in patients with non-valvular chronic heart failure and explore the role of oxidative stress caused by NADPH oxidase p22phox subunit in left ventricular remodeling. Methods Semi-quantitative RT-PCR was used to examine the expression levels of phagocytic NADPH oxidase p22phox in 59 patients with non-valvular chronic heart failure and 20 control subjects. All the subjects underwent ultrasonic cardiography to record their IVST, LVPWT, LVEDd, LVEDs, and EF. Based on the calculated LVMI, the patients were divided into heart failure without LV hypertrophy (LVH) group and heart failure with LVH group. Results The patients with heart failure showed significantly higher expression of phagocytic NADPH oxidase p22phox than the control subjects (0.91±0.37 vs 0.68±0.33, P=0.039), and the patients with LVH had significantly higher p22phox expression than those without LVH (1.58±0.20 vs 0.71±0.24, P=0.026). LVMI showed a positive correlation with the expression of p22phox in these patients (r=0.508, P〈0.05). Conclusion NADPH oxidase p22phox expression level is positively correlated with LVMI and can be indicative of the level of left ventricular remodeling in patients with non-valvular chronic heart failure.
出处 《南方医科大学学报》 CAS CSCD 北大核心 2013年第1期142-144,149,共4页 Journal of Southern Medical University
基金 山东省自然科学基金(2010ZRB1488) 山东临沂市科委科技计划项目(201213043)
关键词 非瓣膜性慢性心衰 左室重量指数 NADPH氧化酶p22phox non-valvular chronic heart failure left ventricular mass index NADPH oxidase p22phox subunit
  • 相关文献

参考文献14

  • 1Wang Y, Lou MF. The regulation of NADPH oxidase and itsassociation with cell proliferation in human [j]. Invest OphthalmolVis Sci, 2009, 50(5): 2291-300.
  • 2Zhang P, Hou M, Li Y, et al. NADPH oxidase contributes tocoronary endothelial dysfunction in the failing heart [j]. Am JPhysiol Heart Circ Physiol, 2009, 296(3): H840-6.
  • 3Wang M, Zhang J, Walker SJ, et al. Involvement of NADPHoxidase in age-associated cardiac remodeling [J], J Mol CellCardiol, 2010,48(4): 765-72.
  • 4Morales MA, Startari U, Rossi G, et al. Reverse left ventricularremodeling is more likely in non ischemic cardiomyopathy patientsupgraded to biventricular stimulation after chronic right ventricularpacing[j]. Cardiovasc Ultrasound, 2011, 9(9): 41.
  • 5侯小玲,赵连友,陈韵岱.血管紧张素转化酶抑制剂和抗氧化剂对湿热应激性大鼠心肌AngⅡ和p22phox表达的影响[J].心脏杂志,2011,23(3):300-303. 被引量:3
  • 6国荣,周娟,邓秀玲,高广道,蒋小英,林元喜.心肌成纤维细胞在血管紧张素Ⅱ作用中活性氧水平及p22^(phox)的表达[J].南方医科大学学报,2009,29(2):202-204. 被引量:5
  • 7Zhao Y, Mclaughlin D, Robinson E,et al. Nox2 NADPH oxidasepromotes pathologic cardiac remodeling associated withDoxorubicin chemotherapy [j]. Cancer Res, 2010,70(22): 9287-97.
  • 8Lu Z, Xu X,Hu X,et al. Oxidative stress regulates left ventricularPDE5 expression in the failing heart[J], Circulation, 2010, 121(13):1474-83.
  • 9Pendyala S, Usatyuk PV, Gorshkova IA, et al. Regulation ofNADPH oxidase in vascular endothelium: the role ofphospholipases, protein kinases, and cytoskeletal proteins [J].Antioxid Redox Signal, 2009, 11(4): 841-60.
  • 10Lo J, Patel VB, Wang Z, et al. Angiotensin converting enzyme 2antagonizes Ang D -induced pressor response and NADPH oxidaseactivation in WKY rats and in SHR model[j]. Exp Physiol, 2012, 97(10): 1113.

二级参考文献28

  • 1刘慧,彭志英.硫代巴比妥酸化学法测定血浆过氧化脂质[J].华西医学,1994,9(3):275-277. 被引量:8
  • 2何丽华,张金良,张颖,王生,叶康平,石红梅,郑小雨,陈斌.高温对大鼠血压及血管活性物质的影响[J].北京大学学报(医学版),2005,37(4):448-448. 被引量:8
  • 3Wolf G, Wenzel UO. Angiotensin Ⅱ and cell cycle regulation [J]. Hypertension, 2004, 43 (3): 693-8.
  • 4Kushiro T, Fujita H, Hisaki R, et al. Oxidative stress in the Dah-saltsensitive hypertensive rat [J]. Clin Exp Hypertens, 2005, 27(1): 9-15.
  • 5Touyz RM. Reactive oxygen species as mediators of calcium signaling by angiotensin Ⅱ: implications in vascular physiology and pathophysiology [J]. Antioxid Redox Signal, 2005, 7 (9-10): 1302-14.
  • 6Rakhee SG, Venkataramana V, Brian M, et al, Upregulation of glucose-6-phosphate dehydrogenase and NAD(P)H oxidase activity increases oxidative stress in failing human heart [J]. J Card Failure, 2007, 13(6): 497-506.
  • 7Katalin S, Bernard L, Philip W, et al. Increased superoxide production in nitrate tolerance is associated with NAD(P)H oxidase and aldehyde dehydrogenase downregulation [J]. J Mol Cell Cardiol, 2007, 42(6): 1111-8.
  • 8Miller FJ Jr, Gutterman DD, Rios CD, et al. Superoxide production in vascular smooth muscle contributes to oxidative stress and impaired relaxation in atherosclerosis[J]. Circ Res, 1998, 82(12): 1298-1305.
  • 9Babior BM. NADPH oxidase: an update [J]. Blood, 1999, 93(5): 1464-76.
  • 10Sorescu D, Weiss D, Lassegue B, et al. Superoxide production and expression of nox family proteins in human atherosclerosis [J]. Circulation, 2002, 105(12): 1429-35.

共引文献6

同被引文献28

  • 1林忠伟,王卓,朱桂平,向定成.血脂康对自发性高血压大鼠血管重构及胶原蛋白的影响[J].中国动脉硬化杂志,2015,23(3):256-260. 被引量:9
  • 2Weitzel LB, Ambardekar AV, Brieke A, et al. Left ventricular assist device effects on metabolic substrates in the failing heart [ J ]. PLoS One, 2013, 8(4) : e60292.
  • 3Perri G, Polito A, Esposito C, et al. Early and late failure of tissue - engineered pulmonary valve conduits used for right ventrieular out- flow tract reconstruction in patients with congenital heart disease [ J]. Eur J Cardiothorac Surg, 2012, 41 (6) : 1320 - 1325.
  • 4Nessler J, Nessler B, Golebiowska - Wiatrak R, et al. Serum bio- markers and clinical outcomes in heart failure patients treated de novo with carvedilol[J]. Cardiol J, 2013, 20(2) : 144 -151.
  • 5Aydogan M, Balta S, Demirkol S, et al. Further studies should eval- uate multiple predispositions in heart failure prognosis [ J ]. Cardiol J, 2013, 20(2) : 211.
  • 6Aronson D, Darawsha W, Atarana A, et al. Pulmonary hyperten- sion, right ventrietdar funetion, and clinical outcome in acute de- compensated heart failure[ J]. J Card Fail, 2013, 19 (10) : 665 - 671.
  • 7Weitzel LB,Ambardekar AV,Brieke A. Left ventricular assist device effects on metabolic substrates in the failing heart[J].PLoS One,2013,(04):e60292.
  • 8Perri G,Polito A,Esposito C. Early and late failure of tissue-engineered pulmonary valve conduits used for right ventricular outflow tract reconstruction in patients with congenital heart disease[J].{H}European Journal of Cardio-thoracic Surgery,2012,(06):1320-1325.
  • 9Nessler J,Nessler B,Golebiowska-Wiatrak R. Serum biomarkers and clinical outcomes in heart failure patients treated de novo with carvedilol[J].Cardiol J,2013,(02):144-151.
  • 10Aydogan M,Balta S,Demirkol S. Further studies should evaluate multiple predispositions in heart failure prognosis[J].Cardiol J,2013,(02):211.

引证文献3

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部